Cargando…

South–West of England’s Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

Purpose: Pirfenidone and nintedanib are two novel antifibrotic agents licensed for the treatment IPF. Prior to being approved for use in England for patients with FVC >50% and <80%, these were made available for all IPF patients under the Mild Patient Program (MPP) and Patient In Need Scheme (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barratt, Shaney L., Mulholland, Sarah, Al Jbour, Khaled, Steer, Henry, Gutsche, Markus, Foley, Noeleen, Srivastava, Rajiv, Sharp, Charles, Adamali, Huzaifa I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6304353/ https://www.ncbi.nlm.nih.gov/pubmed/30618768 http://dx.doi.org/10.3389/fphar.2018.01480

Ejemplares similares

Inhibitors of the Autotaxin-Lysophosphatidic Acid Axis and Their Potential in the Treatment of Interstitial Lung Disease: Current Perspectives
por: Zulfikar, Sabrina, et al.
Publicado: (2020)

Idiopathic Pulmonary Fibrosis (IPF): An Overview
por: Barratt, Shaney L., et al.
Publicado: (2018)

Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis
por: Finnerty, James Patrick, et al.
Publicado: (2021)

Colitis Associated with Nintedanib Therapy for Idiopathic Pulmonary Fibrosis (IPF)
por: Oda, Keishi, et al.
Publicado: (2017)

Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis
por: Flaherty, Kevin R., et al.
Publicado: (2018)

Nintedanib (BIBF 1120) for IPF: a tomorrow therapy?
por: Antoniu, Sabina A
Publicado: (2012)

Nintedanib for non-IPF progressive pulmonary fibrosis: 12-month outcome data from a real-world multicentre observational study
por: Raman, Lavanya, et al.
Publicado: (2023)

Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis
por: Lehtonen, Siri T., et al.
Publicado: (2016)

Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis
por: Belhassen, Manon, et al.
Publicado: (2021)

Clinicoserological features of antisynthetase syndrome (ASyS)-associated interstitial lung disease presenting to respiratory services: comparison with idiopathic pulmonary fibrosis and ASyS diagnosed in rheumatology services
por: Barratt, Shaney L, et al.
Publicado: (2021)

Specialist palliative care, psychology, interstitial lung disease (ILD) multidisciplinary team meeting: a novel model to address palliative care needs
por: Barratt, Shaney L, et al.
Publicado: (2018)

Cost-Effectiveness Analysis of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium
por: Rinciog, C., et al.
Publicado: (2020)

Acute Exacerbation of Idiopathic Pulmonary Fibrosis With Pirfenidone and Nintedanib: A Friend or Foe
por: Kaushal, Mohit, et al.
Publicado: (2022)

Differential Discontinuation Profiles between Pirfenidone and Nintedanib in Patients with Idiopathic Pulmonary Fibrosis
por: Takehara, Kazutaka, et al.
Publicado: (2022)

Evaluation of Pirfenidone and Nintedanib in a Human Lung Model of Fibrogenesis
por: Roach, KM, et al.
Publicado: (2021)

Pirfenidone vs. nintedanib in patients with idiopathic pulmonary fibrosis: a retrospective cohort study
por: Marijic, Pavo, et al.
Publicado: (2021)

IPF Care: A Support Program for Patients with Idiopathic Pulmonary Fibrosis Treated with Pirfenidone in Europe
por: Duck, Annette, et al.
Publicado: (2015)

Pharmacological treatment of idiopathic pulmonary fibrosis – preclinical and clinical studies of pirfenidone, nintedanib, and N-acetylcysteine
por: Myllärniemi, Marjukka, et al.
Publicado: (2015)

Real World Experiences: Pirfenidone and Nintedanib are Effective and Well Tolerated Treatments for Idiopathic Pulmonary Fibrosis
por: Hughes, Gareth, et al.
Publicado: (2016)

Patient expectations, experiences and satisfaction with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a quantitative study
por: Moor, C. C., et al.
Publicado: (2020)

Pharmacological Interactions of Nintedanib and Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis in Times of COVID-19 Pandemic
por: Serra López-Matencio, José M., et al.
Publicado: (2021)

Pirfenidone improves survival in IPF: results from a real-life study
por: Margaritopoulos, George A., et al.
Publicado: (2018)

Effects of hypoxia and hyperoxia on the differential expression of VEGF-A isoforms and receptors in Idiopathic Pulmonary Fibrosis (IPF)
por: Barratt, Shaney L., et al.
Publicado: (2018)

Randomized phase II study of nintedanib with or without pirfenidone in patients with idiopathic pulmonary fibrosis who experienced disease progression during prior pirfenidone administration
por: Ikeda, Satoshi, et al.
Publicado: (2022)

Retrospective Analysis of Medication Utilization and Clinical Outcomes in Patients With Idiopathic Pulmonary Fibrosis Treated With Nintedanib or Pirfenidone
por: Ipatova, Anastasia Y, et al.
Publicado: (2019)

Nintedanib and pirfenidone for idiopathic pulmonary fibrosis in King Abdulaziz Medical City, Riyadh: Real-life data
por: Khan, Mohammed Ayaz, et al.
Publicado: (2023)

A comparison of published multidimensional indices to predict outcome in idiopathic pulmonary fibrosis
por: Sharp, Charles, et al.
Publicado: (2017)

Efficacy of Pirfenidone and Nintedanib in Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis: A Systematic Review
por: Amati, Francesco, et al.
Publicado: (2023)

Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells
por: Molina-Molina, M., et al.
Publicado: (2018)

Interferon-γ enhances the antifibrotic effects of pirfenidone by attenuating IPF lung fibroblast activation and differentiation
por: Vu, Tuong N., et al.
Publicado: (2019)

Effects of Pirfenidone and Nintedanib on Markers of Systemic Oxidative Stress and Inflammation in Patients with Idiopathic Pulmonary Fibrosis: A Preliminary Report
por: Fois, Alessandro G., et al.
Publicado: (2020)

Effectiveness and Safety of Pirfenidone and Nintedanib for Pulmonary Fibrosis in COVID-19-Induced Severe Pneumonia: An Interventional Study
por: Choudhary, Rajkamal, et al.
Publicado: (2022)

A multidisciplinary approach to the diagnosis of antisynthetase syndrome
por: Wells, Matthew, et al.
Publicado: (2022)

Negative impact of anorexia and weight loss during prior pirfenidone administration on subsequent nintedanib treatment in patients with idiopathic pulmonary fibrosis
por: Ikeda, Satoshi, et al.
Publicado: (2019)

Long-Term Follow-Up of Patients With Idiopathic Pulmonary Fibrosis Treated With Pirfenidone or Nintedanib: A Real-Life Comparison Study
por: Cameli, Paolo, et al.
Publicado: (2020)

Long-term nitrofurantoin: an analysis of complication awareness, monitoring, and pulmonary injury cases
por: Speirs, Toby Peter, et al.
Publicado: (2021)

Current and novel drug therapies for idiopathic pulmonary fibrosis
por: Adamali, Huzaifa I, et al.
Publicado: (2012)

Clinical outcomes of dose modification during pirfenidone treatment for IPF: A nationwide post-marketing surveillance study
por: Kang, Jieun, et al.
Publicado: (2023)

Assessing the Effectiveness of Pirfenidone in Idiopathic Pulmonary Fibrosis: Long-Term, Real-World Data from European IPF Registry (eurIPFreg)
por: Krauss, Ekaterina, et al.
Publicado: (2020)

Investigating the effects of nintedanib on biomarkers of extracellular matrix turnover in patients with IPF: design of the randomised placebo-controlled INMARK®trial
por: Maher, Toby M, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_2p91upn24a4555m58po5in8v31